Pentadeca Arginate Reconstitution Calculator

Pentadeca Arginate is a marketed arginine-salt form of the pentadecapeptide BPC-157 (sequence GEPPPGKPADDAGLV, MW 1419); the name is vendor nomenclature, not a distinct chemical entity in the published literature. All pharmacology below refers to the parent peptide. An arginine counterion is plausible as a stabilizing/oral-delivery strategy, since BPC-157 is documented as native and stable in human gastric juice for more than 24 h and active via oral, parenteral, and topical routes (animal evidence). Arginine itself appears throughout BPC-157 studies as a nitric-oxide-system substrate with which the peptide interacts functionally, but no published study tests an arginate salt formulation directly.

No. BPC-157 has no FDA approval, no validated dosing regimen, and no completed Phase II trial; available human data come from fewer than 30 subjects across uncontrolled pilot studies. It is unapproved in standard medicine in the US and EU, and sources describe an illicit gray market supplying it without prescription alongside other unapproved peptides, with risks of contamination, manufacturing impurities, and inaccurate dosing,. Professional sports antidoping rules apply: BPC-157 has been prohibited under WADA Class S0 (unapproved substances) in recent years, so competitive athletes should assume it is banned.

No human dose-response data exist. Animal studies use 10 µg/kg or 10 ng/kg daily, given intraperitoneally, intragastrically, or in drinking water, with roughly equipotent results across routes and both dose levels,. Documented human administrations (pilot/case series):

Community protocols for self-administration typically use 250–500 µg subcutaneously 1–2×/day, or 500 µg–1 mg/day orally for the arginate form (community protocol): these extrapolate from the animal µg/kg range and are not validated in humans.

Both are defensible; neither is validated in humans. Oral dosing works in animals because the peptide resists gastric degradation, and per-oral (drinking water) regimens match intraperitoneal efficacy across tendon, muscle, fistula, and GI injury models. Parenteral pharmacokinetics are known: intramuscular bioavailability is ~14–19% in rats and 45–51% in beagle dogs, with elimination half-life under 30 min and linear kinetics. Biological effects nonetheless persist hours to days, a pharmacokinetic-pharmacodynamic disconnect with uncertain mechanistic explanation. Community practice: inject (SC or near-injury) for musculoskeletal targets, oral for gut and systemic use (community protocol).

Preclinical toxicology is reassuring: single- and repeated-dose studies in mice, rats, rabbits, and dogs showed no serious toxicity, no genetic toxicity, no embryo-fetal toxicity, and only mild local irritation. Human pilots reported no adverse events (IV 10–20 mg; intravesical 10 mg ), but these are tiny and uncontrolled. The dominant real-world risks are supply-side: unregulated sources can carry contaminants, impurities, or inaccurate dosing, and long-term human safety, including carcinogenic and cardiovascular effects of unapproved peptides generally, is unknown,. Pregnancy and lactation: no data; embryofetal tox testing was negative in animals, but this does not establish safety in human pregnancy.

There is no human evidence to define a cycle length. Animal protocols range from single post-injury doses, to 4-week courses, up to 90-day oral regimens; one single-dose spinal-cord study documented sustained recovery out to 1 year. Repeated-dose toxicology in dogs at up to 2 mg/kg found no abnormal changes. Community convention is 4–8 week cycles with time off (community protocol). Given the sub-30-minute plasma half-life, twice-daily dosing is common in community protocols despite the long-lasting pharmacodynamic effects.

In a rat Achilles transection model, TB-500 (60 µg/kg/day IP) produced statistically significant biomechanical improvement at 4 weeks; BPC-157 (10 µg/kg/day) improved numerically without reaching significance for total scores, and combining the two added no benefit over either alone. Mechanistically they are distinct: BPC-157 drives angiogenesis partly through FBXO22-dependent BACH1 stabilization and endothelial tube formation; TB-4/TB-500 is primarily an actin-sequestering, cell-migration peptide. Human data for either are minimal, and dosing/route heterogeneity precludes ranking them,.

The parent peptide is the relevant reference: in liquid serum/plasma compartments, BPC-157 degrades rapidly, while in dried matrices it remained detectable throughout prolonged non-refrigerated storage studies. Community handling practice for lyophilized vials: keep powder frozen or refrigerated; reconstituted peptide refrigerated and used within ~30 days; avoid heat and direct light (community protocol). There are no specific stability data for the arginate salt form.